GLMD (GLMD) Stock Price & Analysis
GLMD (GLMD) rose 11.19% to USD 0.52 as of June 10, 2026 at 06:43 UTC, according to Nexqual real-time market data.
GLMD last closed at USD 0.47; the session ranged USD 0.46–0.58 on volume of 791,472 shares. Market capitalization is $4.01M, with a 52-week range of USD 0.41–2.34 (NCM). Source: Nexqual, June 10, 2026 at 06:43 UTC.
Key Statistics (as of June 10, 2026 at 06:43 UTC)
| Price | USD 0.52 |
|---|---|
| Change | ▲ 11.19% (up) |
| Previous Close | USD 0.47 |
| Open | USD 0.46 |
| Day Range | USD 0.46 – 0.58 |
| 52-Week Range | USD 0.41 – 2.34 |
| Volume | 791,472 shares |
| Market Cap | $4.01M |
| Exchange | NCM |
Technical Analysis (GLMD)
Nexqual's technical model rates GLMD "NEUTRAL" based on 3 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 06:43 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 33.4 (neutral) |
| vs SMA50 | Below (USD 0.63) |
| MACD | 0.01 (positive) |
Analyst Ratings (GLMD)
Wall Street analysts rate GLMD "None", per Nexqual as of June 10, 2026 at 06:43 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (GLMD)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.92 vs est -0.51 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -0.63 vs est -0.83 ▲ beat |
| 2025-03-31 | USD -0.62 vs est -0.89 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:43 UTC.
Financials & Fundamentals (GLMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.21% |
| Current Ratio | 6.55 |
| Total Cash | $18.16M |
| Total Debt | $0 |
| Free Cash Flow | $-3.83M |
Source: Nexqual, June 10, 2026 at 06:43 UTC.
Financial Health Score (GLMD)
Nexqual rates GLMD's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -64%, ROA -28.7% |
Ownership (GLMD)
| Insider Ownership | +3.30% |
|---|---|
| Institutional Ownership | +1.92% |
| Shares Outstanding | 7.68M |
| Float | 6.37M |
| Short % of Float | +0.27% |
Source: Nexqual, June 10, 2026 at 06:43 UTC.
Leadership (GLMD)
GLMD is led by Allen Baharaff (age 60), Co-Founder, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 06:43 UTC.
| Co-Founder, President, CEO & Chairman | Allen Baharaff (age 60) |
|---|---|
| Chief Financial Officer | Doron Cohen (age 58) |
| COO & Data Protection Officer | Guy Nehemya (age 40) |
| Chief Scientific Officer | Liat Hayardeny (age 58) |
Major Backers & Investors (GLMD)
Notable institutional backers of GLMD include Two Sigma Investments, LP, Xtx Topco Ltd, Jane Street Group, LLC, according to Nexqual as of June 10, 2026 at 06:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Two Sigma Investments, LP | 1.4% |
| Xtx Topco Ltd | 0.34% |
| Jane Street Group, LLC | 0.25% |
| Citadel | 0.17% |
Source: Nexqual, June 10, 2026 at 06:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GALT | Galectin Therapeutics Inc. | USD 2.41 | ▲ 3.43% |
| RDHL | Redhill Biopharma Ltd. | USD 0.8 | ▼ 22.33% |
| NCNA | NuCana plc | USD 1.97 | ▲ 1.03% |
| PRQR | ProQR Therapeutics N.V. | USD 1.47 | ▼ 2% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:43 UTC. This page is informational and not investment advice.